AVXL
Anavex Life Sciences Corporation
-22.55%
$11.75 - $9.10
Feb 7th 2023 - Mar 21st 2023
Jan, 23, 2023
“Statistically significant improvements in lung fu... See more
Dec, 3, 2022
Anavex said that the candidate's safety profil... See more
SAVA
Cassava Sciences Inc
-13.96%
$29.88 - $25.71
Feb 7th 2023 - Mar 21st 2023
Mar, 21, 2023
Appears to have a clean safety profile.
Dec, 3, 2022
But what made me invest and hold through the turbu... See more
TGTX
TG Therapeutics Inc
-19.05%
$18.43 - $14.92
Feb 7th 2023 - Mar 21st 2023
Jan, 6, 2023
Blood thinner Eliquis captured significant market ... See more
Jan, 4, 2023
$TGTX paid troll for Goldman or BOA, superb labeli... See more
Jan, 23, 2023
“Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023” Oh, 48 weeks! !
Dec, 3, 2022
Anavex said that the candidate's safety profile also appeared to be relatively good.
Nov, 30, 2022
Anavex also better in ADAS-Cog14, and far superior safety profile.
Nov, 18, 2022
>> no clinically significant treatment-related adverse events and no serious adverse events = PERFECT SAFETY PROFILE !!
Nov, 14, 2022
$AVXL safety profile = excellent !!
Oct, 30, 2022
with Blarcamesine's outstanding safety profile this will become the #1 off label prescribed drug in the world.
Oct, 4, 2022
$AVXL for Hans, yes $avxl is great and will get approved when it’s high dose arm absolutely crushes the current SOC with a flawless safety profile.
Mar, 21, 2023
Appears to have a clean safety profile.
Dec, 3, 2022
But what made me invest and hold through the turbulence was watching Simu's safety profile & performance trend further develop at each trial update--peerless and unassailable.
Oct, 19, 2022
These clinical data combined with a clean safety profile and easy oral administration suggest highly encouraging and durable treatment effects for people living with Alzheimer’s disease.”
Oct, 14, 2022
Simufilam boosts soluble level of Amyloid bera42 which in turn improves or maintains cognition in Alz patients This, along with its superior safety profile, will win the approval undoubtedly!
Jan, 6, 2023
Blood thinner Eliquis captured significant market from Xarelto due to its safety profile.
Jan, 4, 2023
$TGTX paid troll for Goldman or BOA, superb labeling with excellent safety profile and no warning
Jan, 4, 2023
Imagine how much Ubli could be worth to BP now with Briumvi’s best in class product profile.
Dec, 30, 2022
Clear best in class profile, less of a burdensome for pts, less time at care centers and less expensive for providers.